Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIRTIK: PMBL (Ismigen) sublingual tablets to reduce respiratory tract infections in children
2025-524212-11-00Phase 4Authorised
- Sponsor
- Lallemand Pharma
- Start
- Apr 2026
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Airways Infection comparing PMBL (Ismigen) sublingual tablets with Placebo sublingual tablets (2 arms). Primary endpoint: Rate of respiratory tract infections (RTIs). Planned start Apr 2026; status: authorised.
02
Drugs
polyvalent mechanical bacterial lysate
03
Conditions
Airways Infection
Beyond the preview
Go deeper on 2025-524212-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524212-11-00.